Clinical Research Directory

Inclusion Criteria: * Age ≥18 years old, male or female. * Meets the classification criteria for rheumatoid arthritis established by the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) in 2010. * Meeting any of the following treatment conditions with poor efficacy (DAS28 score as moderate-high disease activity) : receiving conventional DMARDs therapy such as methotrexate for at least 3 months; Treatment with biological agents such as TNFi for at least 3 months; Treatment with eramode or tofaciib alone for at least 3 months. * Understand the procedure and content of the test, and voluntarily sign the informed consent. Exclusion Criteria: * Patients with a known allergy to Iguratimod or tofacitinib. * Patients who have previously used eramode or tofaciib and discontinued treatment for safety reasons; * At the time of screening, they are in the acute phase of acute infection or chronic infection; * At screening, hepatitis B DNA and/or hepatitis C RNA screening is positive, indicating viral hepatitis, HBs only Ag-positive healthy carriers were not considered as exclusion criteria, and inclusion of the patient was determined by the investigator; * At the time of screening, have a history of active TB or TB screening suggests latent infection with mycobacterium tuberculosis; * A medical condition or history of congestive heart failure at the time of screening; * Include other ongoing projects or studies; * Severe, progressive, uncontrolled disorders of vital organs and systems, as well as other medical conditions Any circumstances that should not be included in this collection.